Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, volume 15, issue 4, pages 274-280

Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor

Publication typeJournal Article
Publication date2021-10-01
Quartile SCImago
Q4
Quartile WOS
Impact factor0.6
ISSN19907508, 19907516
Biochemistry
Clinical Biochemistry
Molecular Medicine
Abstract
Computer simulation has been used to identify peptides that mimic the natural target of the SARS-CoV-2 coronavirus spike (S) protein, the angiotensin-converting enzyme type 2 (ACE2) cell receptor. Based on the structure of the complex of the protein S receptor-binding domain (RBD) and ACE2, the design of chimeric molecules consisting of two 22–23-mer peptides linked to each other by disulfide bonds was carried out. The chimeric molecule X1 was a disulfide dimer, in which terminal cysteine residues in the precursor molecules h1 and h2 were connected by the S-S bond. In the chimeric molecule X2, the disulfide bond was located in the middle of each precursor peptide molecule. The precursors h1 and h2 mimic amino acid sequences of α1- and α2-helices of the ACE2 extracellular peptidase domain, respectively, keeping intact most of the amino acid residues involved in the interaction with RBD. The aim of the work was to evaluate the binding efficiency of chimeric molecules and their constituent peptides with RBD (particularly in dependence of the middle and terminal methods of fixing the initial peptides h1 and h2). The proposed polypeptides and chimeric molecules were synthesized by chemical methods, purified to 95–97% purity, and characterized by HPLC and MALDI-TOF mass spectrometry. Binding of these peptides to the SARS-CoV-2 RBD was evaluated by microthermophoresis with recombinant domains corresponding in sequence to the original Chinese (GenBank ID NC_045512.2) and the British (B. 1.1.7, GISAID EPI_ISL_683466) variants. The original RBD of the Chinese variant bound to three synthesized peptides: linear h2 and both chimeric variants. Chimeric peptides were also bound to the RBD of the British variant. The antiviral activity of the proposed peptides was evaluated in Vero cell line.

Top-30

Citations by journals

1
Biochemistry (Moscow)
1 publication, 25%
Journal of Enzyme Inhibition and Medicinal Chemistry
1 publication, 25%
ACS Applied Bio Materials
1 publication, 25%
Russian Chemical Reviews
1 publication, 25%
1

Citations by publishers

1
Pleiades Publishing
1 publication, 25%
Taylor & Francis
1 publication, 25%
American Chemical Society (ACS)
1 publication, 25%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 25%
1
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Bibilashvili R. S. et al. Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor // Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2021. Vol. 15. No. 4. pp. 274-280.
GOST all authors (up to 50) Copy
Bibilashvili R. S., Sidorova M., Dudkina U. S., Palkeeva M., Molokoedov A., Kozlovskaya L. I., Egorov A., Ishmukhametov A. A., Parfyonova E. V. Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor // Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2021. Vol. 15. No. 4. pp. 274-280.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1134/s199075082104003x
UR - https://doi.org/10.1134/s199075082104003x
TI - Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor
T2 - Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry
AU - Bibilashvili, R Sh
AU - Sidorova, M.V.
AU - Dudkina, U S
AU - Palkeeva, M.E.
AU - Molokoedov, A.S.
AU - Kozlovskaya, L I
AU - Egorov, A.M
AU - Ishmukhametov, A A
AU - Parfyonova, E V
PY - 2021
DA - 2021/10/01 00:00:00
PB - Pleiades Publishing
SP - 274-280
IS - 4
VL - 15
SN - 1990-7508
SN - 1990-7516
ER -
BibTex |
Cite this
BibTex Copy
@article{2021_Bibilashvili,
author = {R Sh Bibilashvili and M.V. Sidorova and U S Dudkina and M.E. Palkeeva and A.S. Molokoedov and L I Kozlovskaya and A.M Egorov and A A Ishmukhametov and E V Parfyonova},
title = {Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor},
journal = {Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry},
year = {2021},
volume = {15},
publisher = {Pleiades Publishing},
month = {oct},
url = {https://doi.org/10.1134/s199075082104003x},
number = {4},
pages = {274--280},
doi = {10.1134/s199075082104003x}
}
MLA
Cite this
MLA Copy
Bibilashvili, R. Sh, et al. “Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor.” Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, vol. 15, no. 4, Oct. 2021, pp. 274-280. https://doi.org/10.1134/s199075082104003x.
Found error?